Fu Y, Song YL, Liu ZG. Recent developments in immunotherapy approaches for allergic rhinitis. World J Clin Cases 2024; 12(31): 6451-6461 [PMID: 39507117 DOI: 10.12998/wjcc.v12.i31.6451]
Corresponding Author of This Article
Zhong-Guo Liu, MD, Professor, Drug Clinical Trial Unit, First Hospital of Shanxi Medical University, No. 13 Jiefang South Road, Taiyuan 030001, Shanxi Province, China. lzg1810@163.com
Research Domain of This Article
Otorhinolaryngology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2024; 12(31): 6451-6461 Published online Nov 6, 2024. doi: 10.12998/wjcc.v12.i31.6451
Recent developments in immunotherapy approaches for allergic rhinitis
Yu Fu, Yi-Lai Song, Zhong-Guo Liu
Yu Fu, Yi-Lai Song, Zhong-Guo Liu, Drug Clinical Trial Unit, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Author contributions: Fu Y contributed to the manuscript conceptualization, manuscript preparation, methodology, and the final revision of the manuscript; Fu Y and Song YL contributed to the data curation; Liu ZG contributed to the manuscript revision. All authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhong-Guo Liu, MD, Professor, Drug Clinical Trial Unit, First Hospital of Shanxi Medical University, No. 13 Jiefang South Road, Taiyuan 030001, Shanxi Province, China. lzg1810@163.com
Received: March 14, 2024 Revised: July 22, 2024 Accepted: August 16, 2024 Published online: November 6, 2024 Processing time: 181 Days and 3.4 Hours
Core Tip
Core Tip: This comprehensive review thoroughly examines various immunotherapeutic pathways. Each pathway is systematically elucidated, with its distinctive features, mechanisms, and clinical implications highlighted. The review critically assesses the epidemiological landscape of allergic rhinitis, shedding light on its diverse regional characteristics and influencing factors. Furthermore, combining immunotherapy with antibody therapy signifies a promising frontier in severe allergic rhinitis treatment. The review outlines relevant indicators for predicting immunotherapy efficacy, emphasizing the importance of identifying immune cells, cytokines, metabolites, and metabolic pathways associated with treatment outcomes. Despite the proven benefits of immunotherapy, the review candidly addresses its limitations.
